China · Delayed Price · Currency is CNY Getein Biotech Statistics
Total Valuation
Getein Biotech has a market cap or net worth of CNY 4.44 billion. The enterprise value is 4.04 billion.
| Market Cap | 4.44B |
| Enterprise Value | 4.04B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
Getein Biotech has 507.15 million shares outstanding. The number of shares has increased by 1.16% in one year.
| Current Share Class | 507.15M |
| Shares Outstanding | 507.15M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | -13.44% |
| Owned by Insiders (%) | 40.61% |
| Owned by Institutions (%) | 1.57% |
| Float | 283.64M |
Valuation Ratios
The trailing PE ratio is 21.32.
| PE Ratio | 21.32 |
| Forward PE | n/a |
| PS Ratio | 4.26 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.75 |
| P/FCF Ratio | 23.91 |
| P/OCF Ratio | 10.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.70, with an EV/FCF ratio of 21.76.
| EV / Earnings | 19.35 |
| EV / Sales | 3.87 |
| EV / EBITDA | 17.70 |
| EV / EBIT | 29.78 |
| EV / FCF | 21.76 |
Financial Position
The company has a current ratio of 2.32, with a Debt / Equity ratio of 0.23.
| Current Ratio | 2.32 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 2.77 |
| Debt / FCF | 3.40 |
| Interest Coverage | 11.37 |
Financial Efficiency
Return on equity (ROE) is 7.12% and return on invested capital (ROIC) is 5.42%.
| Return on Equity (ROE) | 7.12% |
| Return on Assets (ROA) | 2.18% |
| Return on Invested Capital (ROIC) | 5.42% |
| Return on Capital Employed (ROCE) | 4.76% |
| Weighted Average Cost of Capital (WACC) | 5.14% |
| Revenue Per Employee | 535,523 |
| Profits Per Employee | 107,222 |
| Employee Count | 1,947 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, Getein Biotech has paid 15.91 million in taxes.
| Income Tax | 15.91M |
| Effective Tax Rate | 7.43% |
Stock Price Statistics
The stock price has increased by +11.04% in the last 52 weeks. The beta is 0.25, so Getein Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +11.04% |
| 50-Day Moving Average | 8.42 |
| 200-Day Moving Average | 8.30 |
| Relative Strength Index (RSI) | 62.63 |
| Average Volume (20 Days) | 7,822,381 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Getein Biotech had revenue of CNY 1.04 billion and earned 208.76 million in profits. Earnings per share was 0.41.
| Revenue | 1.04B |
| Gross Profit | 701.79M |
| Operating Income | 135.61M |
| Pretax Income | 214.08M |
| Net Income | 208.76M |
| EBITDA | 221.77M |
| EBIT | 135.61M |
| Earnings Per Share (EPS) | 0.41 |
Balance Sheet
The company has 1.14 billion in cash and 631.03 million in debt, with a net cash position of 509.04 million or 1.00 per share.
| Cash & Cash Equivalents | 1.14B |
| Total Debt | 631.03M |
| Net Cash | 509.04M |
| Net Cash Per Share | 1.00 |
| Equity (Book Value) | 2.80B |
| Book Value Per Share | 5.31 |
| Working Capital | 1.31B |
Cash Flow
In the last 12 months, operating cash flow was 408.38 million and capital expenditures -222.77 million, giving a free cash flow of 185.61 million.
| Operating Cash Flow | 408.38M |
| Capital Expenditures | -222.77M |
| Free Cash Flow | 185.61M |
| FCF Per Share | 0.37 |
Margins
Gross margin is 67.31%, with operating and profit margins of 13.01% and 20.02%.
| Gross Margin | 67.31% |
| Operating Margin | 13.01% |
| Pretax Margin | 20.53% |
| Profit Margin | 20.02% |
| EBITDA Margin | 21.27% |
| EBIT Margin | 13.01% |
| FCF Margin | 17.80% |
Dividends & Yields
This stock pays an annual dividend of 0.18, which amounts to a dividend yield of 2.06%.
| Dividend Per Share | 0.18 |
| Dividend Yield | 2.06% |
| Dividend Growth (YoY) | -5.26% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 49.49% |
| Buyback Yield | -1.16% |
| Shareholder Yield | 0.89% |
| Earnings Yield | 4.70% |
| FCF Yield | 4.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jun 8, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Getein Biotech has an Altman Z-Score of 3.97 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.97 |
| Piotroski F-Score | 6 |